A newer SEC filing has been made since this research was written — check the primary sources before acting on a number here.
A well-run, deleveraging precision-motion roll-up whose ~0.8% organic growth has been lapped by a +99% / 12-month stock that now trades at ~67x P/E and ~24x EV/EBITDA — the SAME EBITDA multiple as Ametek at 1/20th the scale and quality, and ~20-45% above every published analyst target. Quality business, dislocated price. WATCHING / lean BEARISH on valuation, not on the company.
Price
Weekly closes
98.66USD+4.3%robotics -1.7%ALNT · 105 weekly closes to 2026-09-11
Research
The Allient dossier
Researched June 24, 2026
The verdict
A well-run, deleveraging precision-motion roll-up whose ~0.8% organic growth has been lapped by a +99% / 12-month stock that now trades at ~67x P/E and ~24x EV/EBITDA — the SAME EBITDA multiple as Ametek at 1/20th the scale and quality, and ~20-45% above every published analyst target. Quality business, dislocated price. WATCHING / lean BEARISH on valuation, not on the company.
Allient Inc. (NASDAQ: ALNT; incorporated Colorado 1962; HQ Amherst, NY) designs, manufactures and sells precision and specialty controlled-motion components and integrated systems — brushless servo/torque/coreless motors, brush motors, integrated motor-drives, gearmotors/gearing, optical encoders, motion controllers, digital servo drives, power-quality filters/transformers, safety I/O modules, and light-weighting/structural composites.
Business model: component + integrated-solution sales to OEMs and end-customers via a direct salesforce plus reps/distributors, through regional "Allient Solution Centers" (China, Europe, North America) that also do final assembly/integration/test. The strategic arc is component supplier → integrated-solutions provider across three pillars — Motion, Controls, Power ("Allied Nexus" → "Allient").
Four target markets (FY2025 mix): Industrial (factory automation, semicap, power quality for data centers), Vehicle (EPS, off-road/ag, power-sports, LPG/fuel-cell), Medical (surgical robots, infusion pumps, dialysis, ventilators), Aerospace & Defense (guided munitions, UAVs, access control, light-weighting).
Contract structure: mostly short-cycle POs (<1yr), revenue recognized point-in-time at shipment; ~3-9 months backlog conversion. One contract has a significant financing component (immaterial). Payment terms net 30-60. No take-or-pay, no recurring/subscription — this is transactional industrial manufacturing.
Customer concentration:None — "No customers exceed 10% of total sales in 2025 or 2024." Genuinely diversified by customer, market and geography. (Note: the Item-1A risk factor boilerplate says "we depend heavily upon a limited number of customers" — that is template language contradicted by the company's own disclosure and is NOT the real position.)
Customers/suppliers: broad OEM base across the four markets; suppliers limited/qualified for critical raw materials (copper, steel, zinc, rare-earth magnets). Competitors: Ametek, Parker Hannifin, Regal Rexnord + many smaller fragmented players.
Supply Chain
Upstream → Allient → end customer, with named stakeholders where disclosable:
Upstream inputs: raw materials — copper, steel, zinc, rare-earth magnets (NdFeB) — plus electronic components, sourced from "a limited number of suppliers" for technically-qualified parts; the company keeps safety-stock and partners via contracts on sole-source items. Rare-earth magnet dependence is the single most strategically exposed input (China-concentrated supply; an industry-wide chokepoint, not Allient-specific).
Manufacturing footprint: US, Canada, Mexico (Reynosa), Europe (Netherlands, Sweden, Germany, Portugal, Czech Republic, UK), China, New Zealand. Active footprint realignment under "Simplify to Accelerate NOW": a Fabrication/Machining Center of Excellence in Dothan, AL, with assembly transferred to Tulsa, OK and Reynosa, MX.
Channel: direct salesforce + authorized reps/agents/distributors across Asia-Pacific, Europe, Canada, Israel, the Americas; Solution Centers provide regional integration/test.
Chokepoints / single-source dependencies: (1) rare-earth magnets; (2) qualified sole-source component suppliers that require customer re-certification to switch ("redesign work … qualified by our customers" → switching is slow); (3) tariff exposure — Mexico/China/Europe manufacturing with US-bound shipment is directly in the tariff crosshairs. Note: a Feb-2026 US Supreme Court ruling struck certain IEEPA-based 2025 tariffs as unconstitutional; Allient had not yet applied for refunds as of the Q1 filing — a small potential tailwind.
This lens stays partly generic because the filings name input materials and sites but not specific supplier or OEM-customer names (no customer >10%, so none are individually disclosed). That is a real limitation, not an omission.
Competitive Advantages (moats)
What the moat is:integration breadth + designed-in switching costs. Allient's differentiation is the ability to combine electro-magnetic + mechanical + electronic motion expertise into custom-engineered, designed-in subsystems that competitors selling discrete components can't match: "Unlike many of our competitors, we are unique in our ability to provide custom-engineered controlled motion solutions that integrate the products we manufacture." Once a motor/encoder/drive is designed into an OEM's surgical robot or guided-munition, it is qualified, certified and sticky for the product's life — switching means re-qualification.
Strength: moderate, narrow. This is a real but modest moat — engineering know-how + qualification lock-in in a highly fragmented market. It is NOT scale (Ametek/Parker/Regal are far larger), NOT brand premium, NOT network effects, NOT IP fortress (the company holds "several patents" but does not claim a defensible patent estate). E&D spend ~7% of sales ($38.8M FY2025) sustains the know-how moat.
Bargaining power:weak-to-balanced. Against large OEM customers — weak ("customers … can make substantial demands … on product pricing"). Against suppliers — weak on sole-source critical materials, balanced elsewhere. Pricing power is surcharge-based on raw-material inflation ("we may be unable to collect surcharges without … reductions in unit volume"). The 150bps gross-margin gain FY2025 came from mix + restructuring, not pricing power.
Verdict: a competent, defensible niche manufacturer — the moat justifies a mid-cycle industrial multiple, not a growth multiple.
Segments
Allient reports one reportable segment (CODM = CEO, reviews consolidated net income). Disaggregation is by target market and geography only — no segment operating income.
By target market ($000):
Market
Q1-26
Q1-25
YoY
FY2025 mix
Industrial
67,249
62,426
+7.7%
~48%
Vehicle
24,630
22,973
+7.2%
~18%
Medical
19,471
19,102
+1.9%
~14%
Aerospace & Defense
20,475
21,037
−2.7%
~15%
Distribution & Other
7,090
7,265
−2.4%
~5%
Total
138,915
132,803
+4.6%
100%
By geography ($000): North America 89,071 (64%) · Europe 43,878 (32%) · Asia-Pacific 5,966 (4%). FY2025 ~55% US.
Trend & cause: the FY2025 growth engine is Industrial — specifically power-quality solutions for data-center infrastructure (the SNC transformer acquisition feeding the AI-datacenter buildout), plus A&D. The drag is Vehicle (power-sports + truck weakness). Critically, in Q1-2026 the YoY market gains are FX-flattered: total +4.6% headline but organic +0.8% (FX +3.8%). So the segment "growth" is mostly translation, not volume — the underlying industrial cycle is roughly flat-to-soft.
Phase B — Measure performance
Earnings Result (latest print: Q1 FY2026, reported 2026-05-06)
Metric
Q1-26
Q1-25
YoY
Revenue
$138.9M
$132.8M
+4.6% (organic +0.8%)
Gross margin
32.7%
32.2%
+50bps
Operating income
$9.32M
$8.78M
+6%
Operating margin
6.7%
6.6%
flat (down vs 7.7% "same Q" per )
Net income
$5.36M
$3.56M
+51%
Diluted EPS (GAAP)
$0.32
$0.21
+49%
Adjusted diluted EPS
$0.50
$0.46
+9%
Adjusted EBITDA
$17.28M
$17.47M
−1%
Bookings
$158.1M
$137.6M
+15% (Book-to-billNew orders divided by orders filled. Above 1 means the backlog is growing; below 1 means the company is working through it faster than it is replacing it.1.14)
Backlog
$251.0M
$237.3M
+6%
vs consensus: revenue in line; adjusted EBITDA $17.28M MISSED the ~$18.46M estimate by ~6.4%; adjusted EPS $0.50 missed ~$0.53 by ~5.7%.
What drove it: GAAP net income +51% flatters the picture — it's largely lower interest expense (−30% to $2.55M on debt paydown) and lower restructuring/other, NOT operating strength. Operating income only +6%; Adjusted EBITDA actually fell because the FX-driven revenue carried little incremental margin and opex (selling +17%, G&A +12%) rose.
Guidance/tone: no hard numeric guide; FY2026 tax rate 21-23%, Capital expenditureMoney spent on long-lived things — buildings, machines, servers — rather than on running costs. $10-12M. Management framed 2026 as entering "from a much stronger position" (balance sheet, cost structure). Tone = cautiously constructive on a soft-but-stabilizing industrial backdrop.
Balance-sheet flags: clean. Cash $41.2M, total debt ~$184.8M (revolver $122.0M + $50M notes + finance leases $8.0M, less issuance costs), net debt ~$143.6M, leverage ~1.8x Adj EBITDA, in compliance with all covenants (max 3.75x). Inventory $110.1M flat; receivables $91.7M up modestly with revenue — no working-capital red flag.
Market reaction: stock −11.9% to $68.07 on the print — the market punished the EBITDA miss and the organic stall. (Then re-rallied to ~$96 by late June — see Lens 8.)
Unusual vs own history: the quality of the beat is the flag — GAAP EPS +51% while Adjusted EBITDA −1% is a below-the-line, deleveraging-driven beat dressed as operating momentum.
Earnings Calls (sentiment trend)
No transcripts on the shelf (transcripts/ empty); synthesized from filings MD&A + secondary call coverage ``.
Persistent themes (multi-quarter): "Simplify to Accelerate NOW," "One Allient," three-pillar Motion/Controls/Power, margin expansion via structural cost-out, data-center power-quality as the growth headline, balance-sheet strengthening.
Tone shift: through 2024 (industrial downturn, footprint pain) → more confident into 2025/2026 ("much stronger position than a year ago"). The pivot in the story is from "fix the cost base" (defensive) to "scalable foundation for growth" + capital return (the +33% dividend, new Defense Solutions Business Unit).
What they stopped saying: less on acute supply-chain disruption/inventory build; more on data-center and defense demand. What to watch: management keeps invoking "long sales cycles … time from selection to full-rate production can be longer" — a tell that the order-to-revenue conversion of the data-center/defense pipeline is slower than the bookings optics suggest.
Comps
ALNT vs named global peers. Multiples are (mid-2026); ALNT EV/Sales is from filing balances. ROE not sourced per-peer → n/a.
Company
Ticker
Mkt cap
EV/Sales
EV/EBITDA
P/E
Div yield
Allient
ALNT
~$1.63B
~3.0x
~24-25x
~67x
~0.17%
Ametek
AME
~$80B+
n/a
~24x
~27.6x fwd
low
Parker Hannifin
PH
~$80B+
n/a
~22x
~26x fwd
low
Regal Rexnord
RRX
~$14.1B
~3.1x
~14.2x
~20.5x fwd / ~52x ttm
—
Read — this is the crux of the dossier. ALNT, a $554M-revenue, +0.8%-organic, ~14% Adj-EBITDA-margin microcap, trades at the same ~24x EV/EBITDA as Ametek — a ~$80B, 25%+ EBITDA-margin serial compounder — and at a premium to Parker (22x) and a huge premium to Regal Rexnord (14x). On EV/Sales it sits with RRX (~3x) despite materially lower margins and growth. A ~67x P/E on a cyclical industrial with low-single-digit organic growth is a growth-stock multiple on a mid-cycle-industrial business. The peer set does not support the multiple.
Stock-Price Catalysts (>5% moves, last ~5 years + the live dislocation)
The defining fact: ALNT is up ~91-99% over the trailing 12 months; 52-week range $33.33 → $100.01; all-time-high close ~$96-100 in June 2026. The stock has doubled off the 2025 industrial-trough low.
Q4-2025 (Feb/Mar 2026): strong print (Q4 rev +17% to $143.4M, record FY gross margin 32.8%, record OCF $56.7M, net debt −$48.4M, leverage 1.82x) + +33% dividend + new Defense Solutions Business Unit launch → re-rating catalyst.
Q1-2026 (May 6, 2026):−11.9% to $68.07 on the Adj-EBITDA/EPS miss + organic stall.
Late-May → June 2026: sharp recovery from ~$68 to ~$96 (+~40% in ~7 weeks), aided by JPMorgan upgrade to Overweight (PT $80 from $65, 15× FY27E EBITDA) on May 26 and broad AI-datacenter/defense industrial momentum.
Pattern the tape reveals: ALNT trades on (1) the data-center power-quality narrative (the AI-infrastructure halo), (2) defense optionality, and (3) the margin/deleveraging turnaround story — far more than on its actual organic growth, which is ~flat. It is a story/multiple stock right now, and the story is "boring industrial supplier with an AI-and-defense tailwind."
Phase C — Judge people & books
Management
CEO/Chairman/President: Dick (Richard) Warzala — long-tenured leader; oversaw the multi-year transformation from Allied Motion Technologies into Allient, the three-pillar strategy, the 2023 rebrand, and "Simplify to Accelerate NOW." CFO: Jim Michaud. Recent moves: Steve Warzala named President of the new Allient Defense Solutions Business Unit + Corporate VP (a family name in a senior role — watch for related-party/governance optics); Alex Collichio elected VP / Chief Administrative Officer.
Track record (quantified): delivered a genuine operational turnaround — FY2025 vs FY2024: operating income +46% ($30.0M→$44.0M), gross margin +150bps to record 32.8%, net income +67% ($13.2M→$22.0M), GAAP diluted EPS +67% ($0.79→$1.32), Adjusted EPS $1.49→$2.17, record OCF $56.7M, net debt cut $48.4M to $139.7M (leverage 1.82x). That is real, credible execution on cost + capital discipline.
Capital allocation: acquisitive growth (SNC transformers 2024, Sierramotion 2023) + organic E&D (~7% sales) + deleveraging (the FY2025 priority) + a small-but-growing dividend (+33%, payout only ~9%). Mostly value-additive; the SNC/data-center bet is paying off. ROE improving on the turnaround (net income $22M on ~$306M equity ≈ ~7% — modest, rising).
Skin in the game / ownership: insider ownership % n/a (no our figures; proxy/Form-4 not pulled). Warzala's long tenure and family-in-the-business imply alignment, but quantify before relying on it.
Red flags (mild): (1) related-party leases — the company leases certain facilities "from companies for which a member of management is a part owner" (~$0.6M/yr, ~$4.8M future minimum) — disclosed, immaterial, but a governance watch-item; (2) family member running the new Defense unit; (3) heavy reliance on non-GAAP framing (Adjusted EBITDA/EPS materially above GAAP) to tell the story. None are disqualifying.
Archetype:founder-operator-adjacent long-tenured builder (not a founder, but a multi-decade architect) — fits a steady industrial compounder, less a hyper-growth story.
Forensic Red Flags
Forensic pass across IS / BS / CF — every figure from filings.
Revenue recognition: point-in-time at shipment; clean and conservative; one immaterial financing-component contract. Contract liabilities $3.6M (small). Low manipulation surface.
Earnings vs cash: Q1-2026 OCF $6.2M vs net income $5.4M — fine, but OCF fell YoY (from $13.9M) on working-capital swings (receivables/inventory/accrued comp). FY2025 OCF $56.7M vs net income $22.0M — healthy (D&A ~$25M, restructuring). No earnings-quality divergence, but the Q1 OCF drop is worth tracking.
Receivables/inventory vs revenue: receivables $91.7M and inventory $110.1M both roughly flat-to-revenue — no channel-stuffing or inventory-bloat signal. Inventory is 19% of assets and is the Critical Audit Matter (Deloitte) — obsolescence judgment in a slow-cycle business is the key estimate; a 1% write-down = ~$0.05 EPS.
Goodwill/intangibles: goodwill $133.7M (23% of assets) + intangibles $84.9M — combined ~38% of assets from the acquisition history. Single reporting unit; qualitative impairment test passed Oct-2025 ("not at risk"). Acquisition-heavy balance sheet = the main long-run impairment exposure if the data-center/defense thesis disappoints.
SBC: modest ($0.85M/qtr); Adjusted EBITDA add-backs are mostly restructuring + FX + SBC — reasonable, not egregious. But GAAP→non-GAAP gap is large ($0.32 GAAP vs $0.50 adj EPS), so judge on GAAP + cash.
Leverage: ~1.8x, well inside the 3.75x covenant; effective rate 5.05%; $90M of revolver hedged via swaps. Healthy.
Regulatory findings (required):
SEC (EDGAR EFTS — LR + AAER, 2021-2026):0 findings. No Litigation Releases, no AAERs naming Allient.
10-K Item 3 (Legal Proceedings): "involved in certain actions that have arisen out of the ordinary course of business … resolution … will not have a significant adverse effect." No material litigation.
Non-SEC (FTC/DOJ/FDA/CFPB) web search:no material hits for the actual entity. All search results map to similarly-named, unrelated companies (Allied Stone, Ally Financial, Allied Interstate, Alliant Techsystems 1992) — none is Allient/Allied Motion Technologies.
Conclusion:No material regulatory or legal findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-K Item 3 as of 2026-06-24. The only governance footnotes are the disclosed related-party leases and the family-member appointment (Lens 9). Clean books.
Valuation context (the punchline): even on the bull FY2028 Adj EPS ~$4, the stock at ~$96 is 24x bull-case three-years-out adjusted earnings; on FY2026 GAAP ($1.50) it's ~64x. Every published 12-month analyst target ($65-80, avg $70.80) sits 20-45% BELOW the current price.
Forecast NOT logged to our model — --watchlist rule (breadth mode logs no Brier forecast).
Bull vs Bear
Bull case. A genuinely better company than it was two years ago: record margins (32.8% GM, 14% Adj EBITDA), record cash flow ($56.7M OCF), net debt slashed to 1.8x, a structurally lower cost base (Simplify to Accelerate NOW, >$6M annualized savings), and a credible secular demand wedge — power-quality/transformers (SNC) into the AI-data-center buildout, plus a newly-stood-up Defense Solutions unit into a rising global-defense-spend cycle. Diversified (no >10% customer), book-to-bill 1.14, backlog +6%, +33% dividend signaling confidence. If the data-center/defense pipeline converts, mid-single-digit-plus organic growth + operating leverage compounds Adj EPS toward $3-4 by FY2028. Quality industrial, improving returns.
Bear case (2-3 permanent-impairment / de-rating risks). (1) Valuation is the risk — ~67x P/E and ~24x EV/EBITDA on +0.8% organic growth, above every analyst target; a re-rate to a normal industrial 12-15x EV/EBITDA is ~35-45% downside even if estimates hold. (2) The growth is FX, not volume — strip currency and the business is roughly flat; the AI/defense narrative is doing the multiple's heavy lifting and could deflate on one soft print (the −11.9% May reaction is the preview). (3) Cyclical + acquisition-heavy — 38% of assets is goodwill/intangibles; an industrial downturn hits both earnings and impairment.
Pre-mortem (18 months out, thesis broke): the data-center power-quality order surge proved to be a pull-forward/one-time infrastructure bolus, Vehicle stayed in recession, FX reversed, organic went negative two quarters running, the multiple compressed from 24x to 14x EV/EBITDA, and the stock round-tripped from ~$96 to ~$55. The turnaround was real but already fully — over — priced.
Are multiples too high? Yes, unambiguously, on every absolute and relative measure.
Contrarian view (what the market refuses to see): the market is pricing ALNT as an AI-infrastructure/defense growth compounder; it is actually a well-run, low-growth, cyclical motion-components roll-up whose earnings beat was below-the-line deleveraging, not operating acceleration. The re-rating, not the business, is the fragile part.
Devil's Advocate (short-seller)
What structurally breaks the model: an industrial-capex downturn — Allient sells short-cycle components into cyclical OEMs with weak pricing power; a 20-30% volume air-pocket (it has happened — 2024) flows straight to operating deleverage.
Revenue concentration:not customer-concentrated (a genuine strength), but increasingly narrative-concentrated on data-center power-quality and defense; if the data-center transformer order wave normalizes, the entire growth story (and multiple) deflates while the legacy Industrial/Vehicle base remains flat-to-soft.
Why the moat is weaker than bulls think: integration know-how in a highly fragmented market with Ametek/Parker/Regal above it — Allient competes on engineering + price, not durable pricing power; surcharge-based pass-through; ~7% ROE. This is a good niche manufacturer, not a wide-moat compounder.
Most dangerous competitor bulls underestimate: the large diversified players (Ametek, Regal Rexnord) cross-subsidizing into Allient's power-quality/data-center niche with scale and balance sheets ALNT can't match.
Worst capital-allocation / governance items: related-party leases (management part-owner); family member heading the new Defense unit; heavy non-GAAP framing. Minor individually, but a pattern worth pricing.
Assumptions that must hold for ~$96: sustained mid-single-digit-plus organic growth + margin expansion + a permanently elevated 22-25x EV/EBITDA multiple. If growth disappoints 20-30%, FY2027 Adj EPS lands ~$2.20 not ~$2.75, and on a (still-generous) 16x EV/EBITDA the stock is ~$55-60 — i.e., ~40% downside on a multiple normalization + a growth miss.
Single scenario that permanently impairs value: a goodwill/intangible writedown (38% of assets) triggered by a failed data-center/defense ramp into an industrial recession — plausible on a 2-3 year horizon, low-probability in the next 12 months.
Management Questions (ordered by information value)
Q1-2026 organic growth was +0.8% while the stock implies double-digit growth — what is your real, ex-FX, ex-acquisition organic growth target for FY2026-2028, and what underpins it?
How much of the data-center power-quality / transformer (SNC) demand is durable run-rate vs a one-time infrastructure buildout, and what's the backlog visibility beyond 9 months?
Adjusted EBITDA fell YoY in Q1 despite +4.6% revenue — at what organic volume level does operating leverage actually turn positive again?
What is the realistic revenue and margin ramp for the new Defense Solutions Business Unit, and over what timeframe to "full-rate production"?
Rare-earth magnet supply: what's your China-exposure mitigation and the margin impact under a magnet-supply shock or export restriction?
With leverage now at 1.8x, what is the capital-allocation priority stack — M&A vs buybacks vs dividend vs further paydown — and your target leverage?
On the related-party facility leases and the Defense-unit leadership appointment: how does the board ensure arm's-length terms and governance independence?
Tariffs: with manufacturing in Mexico/China/Europe shipping into the US, what is the net annualized tariff exposure, and will you pursue the IEEPA-refund opportunity from the Feb-2026 Supreme Court ruling?
Vehicle has been the persistent drag — is power-sports/truck weakness cyclical or structural, and would you exit/rationalize sub-scale lines?
Gross margin hit a record 32.8% — how much further structural margin is left in Simplify to Accelerate NOW vs how much was cyclical mix?
What is your M&A pipeline and valuation discipline at current industrial multiples — would you issue equity at ~67x to fund a deal?
How do you defend the integration/qualification moat as Ametek/Parker/Regal push into power-quality and data-center motion?
What share of revenue is designed-in / sole-sourced sticky vs re-competed each cycle?
E&D is ~7% of sales — what is the new-product vitality (revenue from products <3 years old), and where is it directed (robotics? data-center? defense?)?
Insider ownership and alignment: what is management's actual equity stake, and are there open-market purchases at current levels?
Company details
Industry
Robotics
Size
Public Company
Others in robotics5 names
Where Allient sits against the other names we cover on this beat. Each line is that company’s verdict, not a summary of it.